Prix Galien Canada – Product Innovation Guidelines
Please download and review the Prix Galien Canada – Product Innovation Guidelines before submitting a nomination.
Transforming Canadians’ lives
Partnering to champion policies that drive the discovery, development and delivery of transformative medicines and vaccines.
BENEFITS OF INNOVATIVE MEDICINES
Real hope for patients and families
New medicines and vaccines save lives and help make our healthcare system more cost‑effective.
Transformation
Preventing or curing disease means extending lives, relieving suffering and improving people’s quality of life.
Safety
Promoting a robust regulatory protocol means ensuring safe and effective medicines for Canadians.
Sustainability
Supporting sustainable healthcare means we all spend more time enjoying life and being productive.
Industry impact In Canada
Better Health Outcomes
47
Innovative Medicines Canada members
107,000
High-quality jobs
$15.9 billion
Yearly economic impact
LATEST RESOURCES
Prix Galien Canada – Product Innovation Award Submission Form
The Prix Galien Canada – Innovative Product Award will be presented to a drug, launched at least 12 months ago and no more than 60 months (5 years) ago, that has made the most significant overall contribution to patient care in Canada, according to the Jury of Prix Galien Canada.
Cost Drivers Report 2023
Annual cost growth in Canada’s private drug benefit market is driven by increased utilization and chronic disease drugs, with an increase in claimants post‑pandemic.
Read the full report.
Two years is too long – Understanding Canada’s Drug Access Pathway
Canadians wait two years for access to new medicines through our public drug plans. That’s a full year longer than patients in most other peer countries. Two years can feel like a lifetime for a patient waiting for access to life-saving medicines or treatments.
Value of Medicines in Canada
This study examines and quantifies the value of innovative treatments in Canada to patient lives, the healthcare system and to society. Case studies include: HPV vaccines, Melanoma treatments, treatment for Rheumatoid Arthritis and Hepatitis C.
Cost of A Private Drug Plan Claim
IMC contracted Reformulary Group to analyze the cost of a private plan prescription drug claim in Canada, and separately in Quebec. This report summarizes that analysis.
LATEST PRESS RELEASES
Press Release December 04, 2023
Innovative pharmaceutical industry statement on COP28 Declaration on Climate and Health
*This statement is available in English only. 3 december 2023, Geneva – The innovative pharmaceutical industry commends the ambition to […]
Press Release November 16, 2023
Innovative Medicines Canada announces scholarship for the University of Guelph’s One Health program
Ottawa, November 16, 2023 – Innovative Medicines Canada (IMC) is pleased to announce a $25,000 scholarship for the University of […]
Press Release November 15, 2023
Pfizer and BioNTech awarded the 2023 Prix Galien Canada Innovative Product Award
Ottawa, November 15, 2023 – Prix Galien Canada is pleased to announce that Pfizer and BioNTech are the recipients of […]
Press Release November 15, 2023
Health Research Foundation announces the recipients of two health research awards
Ottawa, November 15, 2023 – The Health Research Foundation (HRF) of Innovative Medicines Canada (IMC) is pleased to announce that […]
Press Release November 14, 2023
Innovative Medicines Canada welcomes Brigitte Nolet as new Board Chair
Ottawa, November 14, 2023 – Innovative Medicines Canada (IMC) is pleased to announce that Brigitte Nolet, President and CEO of […]
Press Release September 25, 2023
Statement by IMC, AMIIF and PhRMA on Promoting Ethics and Business Integrity in Healthcare
As representatives of the pharmaceutical industry, we strongly support and are active leaders in the Business Ethics for APEC SMEs Initiative, the world’s largest public-private partnership to strengthen ethical business practices in the biopharmaceutical sector.
Press Release September 08, 2023
New report shows economic incentives are needed to effectively fight antimicrobial resistance
Ottawa, September 08, 2023 – Innovative Medicines Canada (IMC) welcomes the release of the Council of Canadian Academies’ (CCA) report […]
Press Release July 05, 2023
IMC calls on Canada’s premiers to improve patient access to medicines
Ottawa, July 5, 2023 – Health care remains top of mind heading into the Council of the Federation Summer Meeting […]
